Science 1st - Evolving treatment paradigm: The convergence of targeted therapy and immunotherapy in oncology

Jun 25 2015

Program Overview:
Tremendous progress has been made in targeted therapy and immunotherapy for the treatment of cancer. However, in an age of convergence and precision medicine, can we combine these parallel treatments to improve outcomes for patients?

Johnson & Johnson Innovation, JLABS (JLABS) is bringing together top experts to discuss the latest developments, challenges and opportunities of combining cancer therapies. Please join Kevan Shokat, Kim Margolin and Iqbal S. Grewal as they present the latest research in this area and engage in a panel discussion with ample time for audience questions.

3:00pm | Registration Opens, Networking
3:25pm | Introduction
3:30pm | Presentation and Q&A
4:30pm | Panel Discussion and Q&A
5:30pm | Networking Reception
7:00pm | Close

Iqbal S. Grewal | Vice President, Head of Immuno-Oncology, Janssen Research & Development, LLC read bio»
Kim Margolin | Adjunct Clinical Professor of Medical Oncology, Stanford University read bio»
Kevan Shokat | Principal Investigator, Howard Hughes Medical Institute read bio»
[moderator] Arturo Molina | Vice President, Oncology Scientific Innovation, Johnson & Johnson Innovation read bio»

$25 General Public - pre-registration will remain open until 12:30pm on June 25th
$15 Student/Academic - pre-registration will remain open until 12:30pm on June 25th
$35 At the door - at the door registration will open at 3:00pm on June 25th

UCSF - Byers Auditorium, Genentech Hall
600 16th St
San Francisco, CA 94158

In Partnership with:

About the Science First series:
The Science First series, sponsored by Johnson & Johnson Innovation, JLABS, brings together top experts to explore pressing topics in their scientific field. It is a chance for local scientists, researchers, and entrepreneurs to present and dialogue on new discoveries, advancing techniques, and other cutting-edge science themes.

Speakers' Biographies:

Iqbal S. Grewal Iqbal S. Grewal, Ph.D., D.Sc., F.R.C.Path | Vice President, Head of Immuno-Oncology, Janssen Research & Development, LLC
Dr. Grewal is Vice President, Head of Immuno-Oncology at Janssen Research & Development, LLC. He leads Janssen's research efforts to discover and develop therapeutics that function as immune modulators cancers, and responsible for formulating and executing Janssen's immuno-oncology strategy. Prior to Janssen, Dr. Grewal led R&D activities at ImmunGene, Inc. as Chief Scientific Officer where he built a diverse portfolio of antibody-cytokine fusion proteins for treating cancers. He was also a member of the Board of Directors. Dr. Grewal joined ImmunGene from Seattle Genetics, Inc. where he was Vice President, Preclinical Therapeutics, and developed monoclonal antibodies and antibody-drug conjugates as therapeutics in the areas of autoimmunity and oncology. Dr. Grewal began his career in industry at Genentech Inc. where he pursued research for discovering and developing innovative protein-based bio-therapeutics in many disease areas. He identified and validated several novel molecules as therapeutic candidates, and translated some of his findings into key drug candidates that successfully moved to clinical development and FDA approval. Dr. Grewal holds a Ph.D in Immunology from UCLA and a D.Sc. from University of Aberdeen, U.K, and has been named a Fellow by the Royal College of Pathologists in London. Dr. Grewal completed his post-doctoral fellowship in Richard Flavell's laboratory at Howard Hughes Medical Institute, Yale University School of Medicine. Dr. Grewal has published numerous papers and holds several patents based on his research. He is also serving on editorial board of research journals and has edited books on biologics and therapeutic targets.
Connect with Iqbal: Connect on LinkedIn

Kim Margolin Kim Margolin, M.D. | Adjunct Clinical Professor of Medical Oncology, Stanford University
Kim Margolin, M.D., is an adjunct clinical professor of medical oncology at Stanford. Her career has been devoted to the study of immunotherapies for solid tumors, particularly melanoma and renal cancer, and she has focused on novel cytokines or combinations as well as investigations of molecularly targeted therapies in these diseases. She has a particular interest in the biology and therapy of melanoma metastatic to the brain and is currently an academic lead investigator for a multi-institution trial of combined immune checkpoint blockade for these patients.
Dr. Margolin has been a member of the Oncology Drugs Advisory Committee to the FDA and is one of the co-principal investigators of the Cancer Immunotherapy Trials Network. She has been active in the leadership of the Society for the Immunotherapy of Cancer since the 1990s and co-leads the Cytokine Working Group in studies of IL-2 and other novel cytokines for solid tumors, mainly renal cancer and melanoma. She has an academic-industry award from the Melanoma Research Alliance and Altor Bioscience for a CITN Phase I-II trial of a novel IL-15 immunoconjugate that is also in promising combinations for solid tumors and hematologic malignancies. This agent may also have a role in adoptive T cell therapy for various solid tumors.
Her other activities include a leadership role in the SWOG Melanoma Committee and the Melanoma Research Alliance (as grant reviewer for the last 6 years), the Melanoma Research Foundation Breakthrough Consortium, and the Society for Melanoma Research. She has served in many capacities the American Society of Clinical Oncology and has lectured extensively on clinical investigation and laboratory correlates of melanoma therapies. She is the section editor for Melanoma of the journal Cancer and has written or co-authored numerous book chapters.
Dr. Margolin was in the Medical Scientist Training Program at Stanford Medical School and did residency in Medicine at Yale. After completing a fellowship in hematology-oncology at UC San Diego and City of Hope, she remained on the faculty at City of Hope for 23 years until her recruitment to lead the renal cancer and melanoma clinical research program at the University of Washington. After 6 years there, she was recruited to Stanford's melanoma group to expand its collaborative efforts

Kevan Shokat Kevan Shokat, Ph.D. | Principal Investigator, Howard Hughes Medical Institute
Professor Shokat is a pioneer in the development of chemical methods for investigating cellular signal transduction pathways—with a particular focus on protein kinases and lipid kinases. Dr. Shokat uses a combination of chemical synthesis and protein engineering to create uniquely traceable and regulatable kinases, allowing the function of over 100 different kinases to be uncovered across all disease areas including oncology, metabolism, and infectious disease.
Kevan is currently an Investigator of the Howard Hughes Medical Institute, Professor in the Department of Cellular and Molecular Pharmacology, where he also served as Department Chair from 2010-2014 at the University of California at San Francisco. He is also Professor in the Department of Chemistry at the University of California at Berkeley. After receiving his Ph.D. in Organic Chemistry at UC Berkeley with Professor Peter Schultz, and post-doctoral work in immunology at Stanford University with Professor Chris Goodnow, Kevan began his independent research career at Princeton University where he was promoted from Assistant to Associate Professor in four years. He has received numerous awards including being named a Fellow of several prestigious research foundations including the Pew Foundation, Searle Foundation, Sloan Foundation, Glaxo-Wellcome Foundation, and the Cotrell Foundation. He has also received the Eli Lilly Award, given to the most promising biological chemist in the country under the age of 37. He was inducted into the National Academy of Sciences (2010), the Institute of Medicine (2011), and the American Academy of Arts and Sciences (2011).
Kevan has successfully commercialized discoveries from his laboratory. His development of chemical genetic tools for tracking and validating protein kinase drug targets is licensed by Artemis-Taconic for target validation of kinases in multiple disease areas. In 2007 he co-founded Intellikine, Inc. to commercialize a series of PI3K and mTOR small molecule inhibitors for cancer and inflammatory disease. In four years Intellikine has progressed three compounds into Phase I including INK1197 (PI3K)-now partnered with Infinity Pharmaceuticals, INK128 (mTOR), and INK1117 (PI3K). In December 2011, Intellikine was acquired by Takeda Pharmaceuticals. In 2013 he co-founded Araxes Pharmaceuticals in La Jolla, CA. Also in 2013 he co-founded eFFECTOR Pharmaceuticals in San Diego, CA.
Connect with Kevan: Connect on Twitter

Arturo Molina [moderator] Arturo Molina, M.D., M.S., F.A.C.P. | Vice President, Oncology Scientific Innovation, Johnson & Johnson Innovation
Dr. Molina is Vice President, Oncology Scientific Innovation at Janssen Research & Development, LLC. He represents the Oncology Therapeutic Area in the California Innovation Center based in Menlo Park, CA. In this role, he is responsible for identifying and fostering innovation that supports the Oncology Therapeutic Area strategies.
Previously he was the Vice President Clinical Research, Oncology, where he was responsible for the clinical development and registration-directed studies of ZYTIGA® (abiraterone acetate) for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). Prior to this role he was the Chief Medical Officer and Executive Vice-President at Cougar Biotechnology, which was acquired by The Johnson & Johnson Family of Companies.
Before joining Cougar Biotechnology, Dr. Molina worked at IDEC as Senior Director, Medical Affairs, ultimately becoming Department Head, Oncology Clinical Development for Biogen-IDEC. In collaboration with Genentech, he led clinical Supplemental Biologics License Application filing activities resulting in the U.S. Food and Drug Administration approval of Rituxan®.
Dr. Molina was a faculty staff physician in Hematology/Bone Marrow Transplantation and Medical Oncology/Therapeutics Research at the City of Hope (COH) Comprehensive Cancer Center, where he became an Adjunct Professor, member of the COH Medical Group Board of Directors and President-Elect of the City of Hope Medical Staff.
Dr. Molina received his medical degree and master’s in Physiology from Stanford University School of Medicine, and continued at Stanford for Residency in Internal Medicine and Fellowships in Medical Oncology, Biological Science, and Bone Marrow Transplantation. Dr. Molina was an undergraduate at the University of Texas at Austin where he received a BS in Zoology (Honors) and BA in Psychology (High Honors).
Connect with Arturo: Connect on LinkedIn